The Elephant in the Room

VAT-TRAP · Naked Heart  ·  Dr Edward Leatham, Consultant Cardiologist

In the past sixty years, cardiovascular medicine has achieved something extraordinary. Heart attack deaths have fallen by more than 70% in the UK and United States. Lives have been saved on a scale that is almost impossible to comprehend. Statins, blood pressure drugs, smoking cessation, and emergency cardiac care have combined to produce one of the greatest triumphs in the history of medicine. And yet, if you look at the data carefully, the rate of improvement is slowing. The progress is still there — but the gradient has changed. Something else is now pushing back.

Read with full references & citations:

https://mhaat.vercel.app/v-sugar-connection-hidden.html

For busy people, or to tune in when on the move, a Google NotebookLM audio podcast is available as a story beneath.

[PODCAST LINK OR TRANSISTOR EMBED — delete this line if no podcast]

A Revolution Worth Celebrating

When we talk about cardiovascular disease, it is easy to forget what 'before' looked like. In 1960, heart disease killed around 700 people per 100,000 in the UK every year — a number so staggering that it was simply considered a fact of middle-aged life. By 2021, that figure had fallen to around 130. In the United States, the same story: 550 per 100,000 down to 150. These are not marginal improvements. This is one of the most dramatic transformations in population health that medicine has ever produced.

The causes are well understood. Millions of people stopped smoking. Blood pressure drugs arrived. Statins lowered cholesterol across entire populations. Surgeons learned to open arteries that had closed. Emergency departments learned to save lives that previously would have been lost within hours of a heart attack. All of this matters enormously and should never be taken for granted.

But here is what the data also show: in India, cardiovascular mortality remains roughly twice that of the UK. Not because the disease is different there, but because hypertension goes untreated, diabetes goes uncontrolled, and preventive care is unevenly available. The lesson from India is the lesson from the 1960s in reverse: when you do not treat the metabolic drivers of heart disease, the numbers are catastrophic. When you do treat them, the numbers fall dramatically.

The first cardiovascular revolution was about treating the consequences of a disease that was already established. The second revolution — the one we need now — is about addressing the causes before they have a chance to establish themselves at all.

Why the Progress Is Slowing

Look at the slope of improvement in the UK and USA over the past decade. The dramatic falls of the 1970s, 1980s, and 1990s have levelled off. Progress has not stopped, but it is measurably slower. And the reason is not mysterious: the populations of both countries are getting fatter, more insulin-resistant, and more metabolically unwell — and these changes are beginning to push back against the gains that pharmacotherapy and smoking cessation have achieved.

The drugs have done much of what they can do. Statins work. Blood pressure drugs work. Smoking cessation programmes work. But obesity rates have more than doubled since the 1980s in both countries. Type 2 diabetes affects more than five million people in the UK and over 37 million in the United States. Visceral fat — the dangerous fat that accumulates around the abdominal organs — is at epidemic levels in adults who might otherwise appear to be at normal or only modestly elevated risk.

We are treading faster on a treadmill that is beginning to accelerate in the opposite direction. The pharmacological gains are real. But the metabolic tide is rising against them.

Are We Fighting the Last War?

The 2026 ACC/AHA Multisociety Dyslipidemia Guideline — endorsed by eleven medical societies — recommends driving LDL cholesterol below 55 mg/dL (1.4 mmol/L) in very high-risk patients, and sets an aspirational goal of below 100 mg/dL (2.6 mmol/L) for all adults. These are not unreasonable recommendations. The relationship between LDL cholesterol and heart disease risk is real, well-established, and extends to very low levels.

But there is a harder question that the guidelines do not fully answer: for a large proportion of the patients we see in clinic today — people with normal or near-normal LDL cholesterol but high visceral fat, elevated ApoB particle count, small dense LDL predominance, and early insulin resistance — is pushing LDL-C still lower really the primary intervention? Or are we intensifying a treatment for a consequence while ignoring the underlying cause?

The parallel from pharmacology is instructive. Every doctor learns the dose-response curve: efficacy rises steeply at low doses, then flattens. Beyond a certain point, doubling the dose adds very little benefit while side-effects climb. The experienced clinician relearns this at the bedside. In hypertension, candesartan 4 mg with spironolactone 25 mg almost always outperforms candesartan 32 mg alone. Two complementary mechanisms at moderate dose beat one mechanism pushed to saturation.

The same principle applies here. Before reaching for a PCSK9 inhibitor to meet the new 55 mg/dL target, the question worth asking is: why is this patient's LDL-C or ApoB elevated? Is it because their LDL receptors are insufficient? Or is it because visceral fat is driving their liver to over-produce small dense LDL particles faster than any receptor can clear them?

Before you prescribe a PCSK9 inhibitor, get your tape measure out. If visceral adiposity is present, you are treating the symptom of a problem you have not addressed yet.

The same question applies to how we use cardiac imaging. CAC scoring — a CT scan that measures the calcium deposited in the coronary arteries — has just received a Class I recommendation in the 2026 ACC/AHA guidelines as a 'tie-breaker' when treatment decisions are uncertain. In the right patient it is genuinely useful. But calcium tells you about the past. It is an archaeological record: the residue of inflammation, plaque formation, and healing that has already happened. It says nothing directly about what is happening right now.

Consider two patients. The first has a high calcium score — but has been on high-intensity statins for ten years. What they have is a large burden of densified, stabilised old plaque. The inflammation has resolved. Their current risk may be considerably lower than the calcium number alone suggests. The second patient has a calcium score of zero — no detectable calcification — but active pericoronary inflammation visible on a CaRi-Heart FAI scan. This is the pre-plaque inflammatory phenotype: the disease trajectory is steep, the plaque has not yet calcified, and the calcium score offers false reassurance. Case studies exactly like this second patient appear in the VAT-TRAP article on coronary calcification at vat-trap.com.

High CAC + low FAI: burnt-out, stabilised disease. Lower current risk than the number implies.  Low/zero CAC + high FAI: active inflammation, no calcification yet. Higher current risk than the number implies.  CAC tells you what has happened. FAI tells you what is happening.

For a patient where metabolic phenotyping is the priority — high visceral fat, pattern B dyslipidaemia, elevated waist-to-height ratio — a CT visceral fat scan (measuring VATI, the visceral adiposity tissue index) is arguably more informative than a calcium score. It quantifies the upstream driver of the problem rather than its downstream residue. And unlike a calcium score, an elevated VATI is actionable: you can reduce it, through the four pillars described below. You cannot un-calcify a coronary artery. Read the full discussion at vat-trap.com/post/is-coronary-artery-calcification-good-or-bad

The Four Diseases We Are Not Talking About Enough

Coronary artery disease is no longer the only — or even the primary — threat to the long-term health of an ageing population in the developed world. Four other disease burdens have grown to rival or exceed it in scale, and all four share a common upstream driver: visceral adiposity and its metabolic consequences.

The VAT-TRAP Four Pillars: A Different Kind of Prevention

The VAT-TRAP framework is built around four treatable risk axes — the four biological pathways that, addressed together, do what no single intervention can do alone. This is the multi-pathway approach that cardiology learned to apply to hypertension in the 1990s: not maximum blockade of one pathway, but moderate, complementary blockade of several.

The Second Cardiovascular Revolution

The first cardiovascular revolution was about treating established disease: opening arteries, lowering cholesterol, controlling blood pressure, and stopping smoking. It saved millions of lives. It is one of medicine's genuine triumphs.

The second cardiovascular revolution needs to address the disease before it establishes itself — by targeting the metabolic conditions that create the substrate for heart disease, dementia, AF, HFpEF, and diabetes all at once. That means visceral fat. That means insulin resistance. That means refined carbohydrate. That means resistance training and lean mass. And that means deploying the new generation of metabolic medicines — GLP-1 and dual GIP/GLP-1 agonists — not as weight-loss drugs, but as the metabolic disease treatment that the evidence increasingly shows them to be.

The elephant in the room is large. It is metabolic. And it is not going away by squeezing LDL-C a few milligrams lower.

Further reading: vat-trap.com  ·  Clinical tools and reference framework: mhaat.vercel.app/reference.html

For educational purposes only. This article represents independent clinical opinion and does not constitute individual medical advice. Please consult a qualified clinician for personal health concerns. © VAT-TRAP · MedicalSpace Ltd 2026.